Phathom Shares Tumble as Impurity Delays Product Launch >PHAT
By Colin Kellaher Shares of Phathom Pharmaceuticals Inc. slid nearly 30% on Tuesday after the biopharmaceutical company said the discovery of trace amounts...
The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: editorial@longbridge.global
Like